26 June 2025
Roquefort Therapeutics plc
("Roquefort Therapeutics" or the "Company")
Results of AGM
Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company focused on developing first in class medicines in the high value and high growth immunology and oncology markets, is pleased to announce that at the Company's Annual General Meeting ("AGM") held earlier today, all resolutions proposed were duly passed.
The resolutions were put to shareholders via a poll, the results of which were as follows:
| Resolution | Poll Results | Total Votes Withheld* | |||
| For | Against | Total Votes Cast | |||
| 1 | Shares | 15,989,492 | 205,120 | 16,194,612 | 289,738 |
| % | 98.73% | 1.27% | |||
| 2 | Shares | 15,758,683 | 432,163 | 16,190,846 | 293,504 |
| % | 97.33% | 2.67% | |||
| 3 | Shares | 15,668,163 | 522,683 | 16,190,846 | 293,504 |
| % | 96.77% | 3.23% | |||
| 4 | Shares | 15,842,448 | 352,163 | 16,194,611 | 289,739 |
| % | 97.83% | 2.17% | |||
| 5 | Shares | 15,842,449 | 352,163 | 16,194,612 | 289,738 |
| % | 97.83% | 2.17% | |||
| 6 | Shares | 15,989,492 | 205,120 | 16,194,612 | 289,738 |
| % | 98.73% | 1.27% | |||
| 7 | Shares | 15,989,492 | 205,120 | 16,194,612 | 289,738 |
| % | 98.73% | 1.27% | |||
| 8 | Shares | 15,671,929 | 522,683 | 16,194,612 | 289,738 |
| % | 96.77% | 3.23% | |||
| 9 | Shares | 15,636,863 | 557,749 | 16,194,612 | 289,738 |
| % | 96.56% | 3.44% | |||
* Votes withheld are not counted in the calculation of the proportion of votes for and against a resolution.
The total number of ordinary shares in issue on 24 June 2025, the deadline for casting votes by proxy in advance of the AGM, was 157,444,030 shares. 10.3% of voting capital was instructed in respect of the resolutions put to the AGM.
Enquiries:
| Roquefort Therapeutics plc | +44 (0)20 3918 8633 |
| Stephen West (Chairman) / Dr Darrin Disley (Interim MD) | |
| SP Angel Corporate Finance LLP (Broker) David Hignell / Vadim Alexandre / Devik Mehta | +44 (0) 20 3470 0470
|
| Burson Buchanan (Public Relations) Ben Romney / Jamie Hooper | +44 (0)20 7466 5000
|
| Peak IR (Investor Relations) Seb Wykeham | +33 (0)7 44 44 15 42 |
LEI: 254900P4SISIWOR9RH34
About Roquefort Therapeutics
Roquefort Therapeutics (LSE:ROQ) is developing first in class drugs in the immunology and oncology markets prior to securing a value accretive exit.
Roquefort Therapeutics' portfolio consists of five novel patent-protected pre-clinical anti-cancer and immunology assets.
For further information on Roquefort Therapeutics, please visit www.roquefortplc.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.